Evidence map›Paper›PMID 29931444›Full record

ArticleHistochemistry and cell biology2018

Wharton's jelly-derived mesenchymal cells as a new source for the generation of microtissues for tissue engineering applications.

D Durand-Herrera, F Campos, B D Jaimes-Parra, J D Sánchez-López, R Fernández-Valadés, M Alaminos, A Campos, V Carriel

Abstract read
PubMed Publisher
In one paragraph

Article in Histochemistry and cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

D Durand-HerreraDepartment of Histology, Tissue Engineering Group, University of Granada, Granada, Spain.
F CamposDepartment of Histology, Tissue Engineering Group, University of Granada, Granada, Spain.
B D Jaimes-ParraDepartment of Histology, Tissue Engineering Group, University of Granada, Granada, Spain.
J D Sánchez-LópezDivision of Maxillofacial Surgery, University Hospital Complex of Granada, Granada, Spain.
R Fernández-ValadésInstituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
M AlaminosDepartment of Histology, Tissue Engineering Group, University of Granada, Granada, Spain.
A CamposDepartment of Histology, Tissue Engineering Group, University of Granada, Granada, Spain. acampos@ugr.es.
V CarrielDepartment of Histology, Tissue Engineering Group, University of Granada, Granada, Spain. vcarriel@ugr.es.ORCID http://orcid.org/0000-0002-8114-5644
Universidad de Granada · ESInstituto de Investigación Biosanitaria de Granada · ES

Funding

Conserjería de Salud de la junta de Andalucía, España CS PI-0257-2017Conserjería de Salud de la junta de Andalucía, España SAS PI-400-2016Plan nacional de investigación Cientítica, Desarrollo e Innovación Tecnológica, del Ministerio de Economía y Competitividad (Institutos de Salud Carlos III). Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea FIS PI17/391Plan nacional de investigación Cientítica, Desarrollo e Innovación Tecnológica, del Ministerio de Economía y Competitividad (Institutos de Salud Carlos III). Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea FIS PI17/393
6 · The paper itself

Abstract

Microtissues (MT) are currently considered as a promising alternative for the fabrication of natural, 3D biomimetic functional units for the construction of bio-artificial substitutes by tissue engineering (TE). The aim of this study was to evaluate the possibility of generating mesenchymal cell-based MT using human umbilical cord Wharton's jelly stromal cells (WJSC-MT). MT were generated using agarose microchips and evaluated ex vivo during 28 days. Fibroblasts MT (FIB-MT) were used as control. Morphometry, cell viability and metabolism, MT-formation process and ECM synthesis were assessed by phase-contrast microscopy, functional biochemical assays, and histological analyses. Morphometry revealed a time-course compaction process in both MT, but WJSC-MT resulted to be larger than FIB-MT in all days analyzed. Cell viability and functionality evaluation demonstrated that both MT were composed by viable and metabolically active cells, especially the WJSC during 4-21 days ex vivo. Histology showed that WJSC acquired a peripheral pattern and synthesized an extracellular matrix-rich core over the time, what differed from the homogeneous pattern observed in FIB-MT. This study demonstrates the possibility of using WJSC to create MT containing viable and functional cells and abundant extracellular matrix. We hypothesize that WJSC-MT could be a promising alternative in TE protocols. However, future cell differentiation and in vivo studies are still needed to demonstrate the potential usefulness of WJSC-MT in regenerative medicine.

Indexed as

Cell SurvivalExtracellular MatrixHumansMesenchymal Stem CellsTissue EngineeringWharton JellyHuman fibroblastHuman Wharton-jelly mesenchymal cellsMesenchymal stem cellsMicroaggregatesMicrotissuesNatural biomaterialTissue engineering

Identifiers

PMID29931444
OpenAlexW2808107361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.